Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

@article{Leonard2006ProteasomeIW,
  title={Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.},
  author={John P. Leonard and Richard R. Furman and Morton Coleman},
  journal={International journal of cancer},
  year={2006},
  volume={119 5},
  pages={971-9}
}
The incidence of non-Hodgkin's lymphoma (NHL) has markedly increased in the US and other westernized countries in recent years and presents a considerable clinical challenge. NHL is divided into subtypes that follow an aggressive or indolent course. Follicular lymphoma (FL), the most common indolent subtype, and mantle cell lymphoma (MCL), an aggressive subtype that accounts for approximately 5% of cases, are generally incurable. MCL has a relatively poor prognosis, with a median survival of 3… CONTINUE READING